{"id":"W4399480854","doi":"10.1200/jco.2024.42.16_suppl.7503","title":"DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Medicine; Daratumumab; Bortezomib; Dexamethasone; Internal medicine; Oncology; Multiple myeloma; Refractory (planetary science)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009270899,0.001973761,0.004884462,0.0008287241,0.0003882952,0.001606715,0.001670432,0.00133838,0.005093063],"category_scores_gemma":[0.007294686,0.0007628582,0.01233878,0.0009980857,0.0004250701,0.0008548435,0.00136458,0.002537712,0.0008147904],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00130949,"about_ca_system_score_gemma":0.002175154,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001582158,"about_ca_topic_score_gemma":0.009463772,"domain_scores_codex":[0.9960375,0.002686507,0.000389421,0.0003215162,0.0003320045,0.0002330407],"domain_scores_gemma":[0.9965674,0.00144453,0.0008433661,0.0004498274,0.0002289932,0.0004659002],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.798986,0.001558317,0.01448821,0.006858125,0.07715242,0.000236027,0.0002053241,0.002698547,0.005969806,0.0004629685,0.02304971,0.06833453],"study_design_scores_gemma":[0.7340741,0.03672413,0.07109531,0.00083475,0.1177756,0.0006626802,0.0002888455,0.002816024,0.001819393,0.002472993,0.03121873,0.0002173679],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7897806,0.09301597,0.005885046,0.006701674,0.00198465,0.01242641,0.08065053,0.0005797081,0.008975394],"genre_scores_gemma":[0.8651416,0.01765308,0.01084859,0.005799097,0.001232407,0.01581104,0.07741065,0.000346584,0.00575697],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009270899,"threshold_uncertainty_score":0.04902977,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1691857205432594,"score_gpt":0.5092422431011188,"score_spread":0.3400565225578593,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}